Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146


Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.

Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC Jr.

Cell Cycle. 2006 Aug;5(15):1654-61. Epub 2006 Aug 1.


Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL.

Cancer Res. 2002 Jul 15;62(14):4132-41.


HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.

Le XF, Pruefer F, Bast RC Jr.

Cell Cycle. 2005 Jan;4(1):87-95. Epub 2005 Jan 10. Review.


FOXO1A is a target for HER2-overexpressing breast tumors.

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.

Cancer Res. 2010 Jul 1;70(13):5475-85. doi: 10.1158/0008-5472.CAN-10-0176. Epub 2010 Jun 15.


Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells.

Ni HJ, Chang YN, Kao PH, Chai SP, Hsieh YH, Wang DH, Fong JC.

Biochim Biophys Acta. 2012 Dec;1820(12):1893-900. doi: 10.1016/j.bbagen.2012.08.002. Epub 2012 Aug 10.


The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr.

J Biol Chem. 2003 Jun 27;278(26):23441-50. Epub 2003 Apr 16.


Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.

Breast Cancer Res Treat. 2010 Sep;123(2):387-96. doi: 10.1007/s10549-009-0649-x. Epub 2009 Nov 28.


Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis.

Shen WH, Yin Y, Broussard SR, McCusker RH, Freund GG, Dantzer R, Kelley KW.

J Biol Chem. 2004 Feb 27;279(9):7438-46. Epub 2003 Dec 16.


CDK inhibitors selectively diminish cell cycle controlled activation of the histone H4 gene promoter by p220NPAT and HiNF-P.

Mitra P, Ghule PN, van der Deen M, Medina R, Xie RL, Holmes WF, Ye X, Nakayama KI, Harper JW, Stein JL, Stein GS, van Wijnen AJ.

J Cell Physiol. 2009 May;219(2):438-48. doi: 10.1002/jcp.21687.


ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL.

Cancer Res. 2001 Sep 1;61(17):6583-91.


Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.

Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL.

Anticancer Drugs. 2012 Apr;23(4):370-9. doi: 10.1097/CAD.0b013e32834f6ea8.


Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway.

Langley B, Thomas M, McFarlane C, Gilmour S, Sharma M, Kambadur R.

Oncogene. 2004 Jan 15;23(2):524-34.


Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6. doi: 10.1073/pnas.1014835108. Epub 2011 Feb 14.

Items per page

Supplemental Content

Write to the Help Desk